RNS Number : 6178M
ValiRx PLC
13 January 2023

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE ANY SECURITIES OF THE COMPANY.

ValiRx PLC

("**ValiRx**" or "**Company**")

Launch of Broker Offer to raise a maximum of £500,000

- ValiRx (AIM: VAL) announces a Broker Offer through Turner Pope Investments (TPI) Limited ("**TPI**").
- The Issue Price of the Broker Offer is 11 pence per New Ordinary Share.
- Every 4 (four) Broker Offer shares issued will have 1 (one) Fundraise Warrant attached, exercisable at 14 pence per Fundraise Warrant, for a period of 36 months from admission of the Broker Offer shares.
- The Broker Offer is for a maximum of £500,000.
- Existing Shareholders or other interested parties who wish to register their interest in participating in the Broker Offer should click on the following TPI platform link: ValiRx - TPI Broker Offer (URL: https://forms.office.com/e/7RAikAA4ce)
- All bids communicated to TPI under the Broker Offer are subject to review and acceptance by the Company and TPI and priority will be given to Existing Shareholders in the event of oversubscription.
- The Broker Offer remains open until 5 p.m. on Monday, 16 January 2023.
- All Broker Offer Shares will be allocated subject to shareholders' approval at a general meeting expected to take place on 2 February 2023.

Turner Pope Broker Offer

ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to announce that it wishes to provide Existing Shareholders (as defined below) and other investors who did not participate in the Fundraising announced today the opportunity to invest in the Company. Accordingly, under the Placing Agreement, TPI has been granted an option in the form of a Broker Offer under which TPI will, as agent for the Company, invite subscriptions for additional new Shares with a value of up to £500,000 at the Issue Price. The maximum number of new Shares to be issued under the Broker Offer at the Issue Price is 4,545,454. The maximum number of Fundraise Warrants to be issued under the Broker Offer is 1,136,363.

The Broker Offer opens immediately and will close at 5 p.m. on Monday, 16 January 2023.

As far as is practical, participation in the Broker Offer will be prioritised for shareholders (direct or indirect) on the register of members of the Company at the close of business on 12 January 2023 ("**Existing Shareholders**"). If the expected maximum subscription under the Broker Offer is taken up, it will raise an additional £500,000, before expenses.

Existing Shareholders or other interested parties who wish to register their interest in participating in the Broker Offer should click on the following TPI platform link: ValiRx - TPI Broker Offer (URL: https://forms.office.com/e/7RAikAA4ce)

A further announcement will be made following the end of the period during which the Broker Offer is open. If the Broker Offer is not fully subscribed by 5 p.m. on 16 January 2023, orders from eligible investors will be satisfied in full, and the balance of the Broker Offer shall lapse.

General Meeting

Completion of the Broker Offer is conditional on the Fundraising Resolutions being passed at the General Meeting, which is expected to take place on 2 February 2023. Admission of the Broker Offer Shares is expected on or around 6 February 2023. Further detail on the General Meeting and key dates for admission of Broker Offer Shares to trading on AIM are contained in the RNS detailing the Fundraising, also issued today, and will be available in the Circular to be published to the Company's website www.valirx.com

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement also issued today.

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	**Tel: +44 (0) 2476 796496** **www.valirx.com** Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker	**Tel: +44 (0) 20 3657 0050**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOESFASFDEDSEFF